Comparative Pharmacology
Head-to-head clinical analysis: FLOVENT DISKUS 250 versus FLUDROCORTISONE ACETATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLOVENT DISKUS 250 versus FLUDROCORTISONE ACETATE.
FLOVENT DISKUS 250 vs FLUDROCORTISONE ACETATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluticasone propionate is a corticosteroid with potent anti-inflammatory activity. It binds to the glucocorticoid receptor, leading to inhibition of pro-inflammatory cytokines, reduction of eosinophil recruitment, and suppression of airway hyperresponsiveness.
Mineralocorticoid receptor agonist; promotes sodium reabsorption and potassium excretion in renal distal tubules, increasing extracellular fluid volume. Also has glucocorticoid activity.
250 mcg inhaled orally via DISKUS twice daily (500 mcg total daily dose).
0.1 mg orally once daily, range 0.05-0.2 mg/day
None Documented
None Documented
Approximately 10-12 hours (terminal elimination half-life in asthmatics).
Terminal elimination half-life is 3.5 hours (range 2–5 h); clinical effect duration exceeds half-life due to mineralocorticoid receptor binding.
Renal (approximately 5% as unchanged drug); fecal (majority as metabolites and unabsorbed drug).
Renal (80%) as inactive metabolites; less than 5% unchanged; minor biliary/fecal elimination.
Category C
Category D/X
Corticosteroid
Corticosteroid